Search Results - "Alperovich, Gabriela"

Mammalian target of rapamycin pathway blockade slows progression of diabetic kidney disease in rats by LLOBERAS, Nuria, CRUZADO, Josep M, FRANQUESA, Marcella, HERRERO-FRESNEDA, Immaculada, TORRAS, Joan, ALPEROVICH, Gabriela, RAMA, Inés, VIDAL, August, GRINYO, Josep M

“…Recent data suggest that the phosphatidylinositol 3-kinase (PI3-K)/Akt/mammalian target of rapamycin (mTOR) pathway is important in diabetic nephropathy. The…”
Get full text

A Qualitative Research for Defining Meaningful Attributes for the Treatment of Inflammatory Bowel Disease from the Patient Perspective by Louis, Edouard, Ramos-Goñi, Juan M., Cuervo, Jesus, Kopylov, Uri, Barreiro-de Acosta, Manuel, McCartney, Sara, Rosenfeld, Greg, Bettenworth, Dominik, Hart, Ailsa, Novak, Kerri, Donnet, Xavier, Easton, David, Saldaña, Roberto, Protze, Katja, Tzur, Eyal, Alperovich, Gabriela, Casellas, Francesc

“…Introduction Crohn’s disease (CD) and ulcerative colitis (UC) are chronic, inflammatory bowel diseases (IBD). Each class and type of medication available for…”
Get full text

Epidemiology, Treatment Patterns, and Cost Analysis of Immune Thrombocytopenia in Spain between 2014 and 2020: A Population-based Study by González-López, Tomás J, Alperovich, Gabriela, Burillo, Elena, Espejo-Saavedra Soler, Marta, Rebollo-Gómez, Elena, Hernández, Ignacio, Justicia, Jose L, Lozano, María L

“…Immune thrombocytopenia (ITP) is characterised by low platelet counts and often leads to bleeding, fatigue, and reduced health-related quality of life.  This…”
Get full text

Regression of Advanced Diabetic Nephropathy by Hepatocyte Growth Factor Gene Therapy in Rats by CRUZADO, Josep M, LLOBERAS, Nuria, TORRAS, Joan, RIERA, Marta, FILLAT, Cristina, HERRERO-FRESNEDA, Immaculada, ARAN, Josep M, ALPEROVICH, Gabriela, VIDAL, August, GRINYO, Josep M

“…Regression of Advanced Diabetic Nephropathy by Hepatocyte Growth Factor Gene Therapy in Rats Josep M. Cruzado 1 , Núria Lloberas 2 , Joan Torras 1 , Marta…”
Get full text

Efficacy and safety of risankizumab for active psoriatic arthritis: 24-week results from the randomised, double-blind, phase 3 KEEPsAKE 2 trial by Östör, Andrew, Van den Bosch, Filip, Papp, Kim, Asnal, Cecilia, Blanco, Ricardo, Aelion, Jacob, Alperovich, Gabriela, Lu, Wenjing, Wang, Zailong, Soliman, Ahmed M, Eldred, Ann, Barcomb, Lisa, Kivitz, Alan

“…Risankizumab is an interleukin-23 inhibitor under study for the treatment of patients with psoriatic arthritis (PsA). The phase 3 KEEPsAKE 2 trial investigated…”
Get more information

The hepatocyte growth factor mimetic, ANG-3777, in kidney transplant recipients with delayed graft function: Results from a randomized phase 3 trial by Vincenti, Flavio, Bromberg, Jonathan, Kim, Jim, Faravardeh, Arman, Leca, Nicolae, Alperovich, Gabriela, Csomor, Philipp Andreas, Aslam, Shakil, Neylan, John

“…In kidney transplant recipients, delayed graft function increases the risk of graft failure and mortality. In a phase 3, randomized, double-blind,…”
Get full text

Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-Up in the Pyramid Registry by DʼHaens, Geert, Reinisch, Walter, Panaccione, Remo, Satsangi, Jack, Petersson, Joel, Bereswill, Mareike, Arikan, Dilek, Perotti, Eva, Robinson, Anne M, Kalabic, Jasmina, Alperovich, Gabriela, Thakkar, Roopal, Loftus, Edward V

“…Real-world, prospective, long-term studies in Crohn's disease (CD) characterizing adalimumab safety data and lymphoma risk were lacking. We present the final…”
Get full text

26186 Efficacy and safety of continuous risankizumab every 12 weeks beyond 3 years of follow-up: An interim analysis of the LIMMitless open-label extension trial by Papp, Kim A., Lebwohl, Mark G., Puig, Lluís, Zeng, Jiewei, Rubant, Simone, Sinvhal, Ranjeeta, Zhao, Yiwei, Alperovich, Gabriela, Leonardi, Craig

Get full text

Glomerular Enlargement Assessed by Paired Donor and Early Protocol Renal Allograft Biopsies by Alperovich, Gabriela, Maldonado, Rafael, Moreso, Francesc, Fulladosa, Xavier, Grinyó, Josep M., Serón, Daniel

Get full text

Adalimumab Effectiveness Up to Six Years in Adalimumab-naïve Patients with Crohn's Disease: Results of the PYRAMID Registry by Loftus, Edward V, Reinisch, Walter, Panaccione, Remo, Berg, Sofie, Alperovich, Gabriela, Bereswill, Mareike, Kalabic, Jasmina, Petersson, Joel, Thakkar, Roopal, Robinson, Anne M, D'Haens, Geert

“…PYRAMID was an international multicenter, noninterventional, postmarketing registry assessing long-term safety and effectiveness of adalimumab (Humira), as…”
Get full text

Tu1732 – Changes in Simplified Endoscopic Score for Crohn's Disease (SES-CD) During a 16-Week Induction Treatment with Upadacitinib: Analysis of the Randomised Controlled Celest Study by Feagan, Brian G., Sandborn, William J., Schreiber, Stefan, Huang, Bidan, Alperovich, Gabriela, Pangan, Aileen L., Lacerda, Ana P., D'Haens, Geert R.

Get full text

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis by Blauvelt, Andrew, Gordon, Kenneth B., Lee, Patricia, Bagel, Jerry, Sofen, Howard, Lockshin, Benjamin, Soliman, Ahmed M., Geng, Ziqian, Zhan, Tianyu, Alperovich, Gabriela, Stein Gold, Linda

“…Risankizumab is approved for treatment of moderate to severe plaque psoriasis. Availability of a patient-controlled single self-injection of risankizumab may…”
Get full text

The effects of concomitant immunomodulators on the pharmacokinetics, efficacy and safety of adalimumab in paediatric patients with Crohn’s disease: a post hoc analysis by Hyams, Jeffrey S., Dubinsky, Marla, Rosh, Joel, Ruemmele, Frank M., Eichner, Samantha F., Maa, Jen‐Fue, Lazar, Andreas, Alperovich, Gabriela, Mostafa, Nael M., Robinson, Anne M.

“…Summary Background In the IMAgINE 1 study, adalimumab induced and maintained remission of moderate‐to‐severe Crohn's disease in children. Aim To assess the…”
Get full text

672 Defining Meaningful Attributes for the Treatment of IBD From Patients' Perspective by Louis, Edouard, Ramos, Juan, Cuervo, Jesus, Kopylov, Uri, Barreiro de Acosta, Manuel, McCartney, Sara, Rosenfeld, Greg, Bettenworth, Dominik, Hart, Ailsa, Novak, Kerri, Donnet, Xavier, Easton, David, Saldana, Roberto, Protze, Katja, Tzur, Eyal, Lehrer, Gabriela Alperovich, Casellas, Francesc

“…INTRODUCTION: Crohn's disease (CD) and ulcerative colitis (UC) are chronic, debilitating inflammatory bowel diseases (IBD). Medications used to treat IBD pts…”
Get full text

Sa1755 - Rapidity of Clinical and Laboratory Improvements Following Upadacitinib Induction Treatment: Data from the Celest Study by Schreiber, Stefan, Peyrin-Biroulet, Laurent, Boland, Brigid S., Higgins, Peter D., Armuzzi, Alessandro, Terdiman, Jonathan P., Zhou, Wen, Alperovich, Gabriela, Cataldi, Fabio, Goteti, Venkata Sasikiran, Lacerda, Ana P.

Get full text

Open : Lymphoma Risk and Overall Safety Profile of Adalimumab in Patients With Crohn's Disease With up to 6 Years of Follow-up in the PYRAMID Registry by D'Haens, Geert, Reinisch, Walter, Panaccione, Remo, Satsangi, Jack, Petersson, Joel, Bereswill, Mareike, Arikan, Dilek, Perotti, Eva, Robinson, Anne M, Kalabic, Jasmina, Alperovich, Gabriela, Thakkar, Roopal, Loftus, Edward V

Get full text

Efficacy of Adalimumab for Treatment of Perianal Fistula in Children with Moderately to Severely Active Crohn's Disease: Results from IMAgINE 1 and IMAgINE 2 by Ruemmele, Frank M, Rosh, Joel, Faubion, William A, Dubinsky, Marla C, Turner, Dan, Lazar, Andreas, Eichner, Samantha, Maa, Jen-Fue, Alperovich, Gabriela, Robinson, Anne M, Hyams, Jeffrey S

“…Adalimumab has been shown to be more effective than placebo in healing fistulae in adults with moderately to severely active Crohn's disease. The efficacy and…”
Get full text

Adalimumab Long-term Effectiveness in Adalimumab-Naive Patients With Crohnʼs Disease: Final Data From PYRAMID Registry: 657 by Loftus, Edward V., DʼHaens, Geert, Reinisch, Walter, Satsangi, Jack, Panaccione, Remo, Berg, Sofie, Alperovich, Gabriela, Bereswill, Mareike, Kalabic, Jasmina, Skup, Martha, Petersson, Joel, Robinson, Anne M.

Get full text

PYRAMID Registry: Long-term Safety and Effectiveness of Adalimumab by Baseline Immunomodulator Use in Patients With Crohnʼs Disease: 694 by Reinisch, Walter, Panaccione, Remo, DʼHaens, Geert, Loftus, Edward V., Satsangi, Jack, Colombel, Jean-Frederic, Alperovich, Gabriela, Berg, Sofie, Kalabic, Jasmina, Bereswill, Mareike, Petersson, Joel, Robinson, Anne M.

Get full text

PYRAMID Registry: Long-term Safety of Adalimumab by Age in Patients With Crohnʼs Disease: 717 by Colombel, Jean-Frederic, DʼHaens, Geert, Reinisch, Walter, Loftus, Edward V., Panaccione, Remo, Satsangi, Jack, Alperovich, Gabriela, Berg, Sofie, Kalabic, Jasmina, Bereswill, Mareike, Petersson, Joel, Robinson, Anne M.

Get full text